Iterative Health has acquired three cardiology research sites located in Beaumont, Port Arthur and Waco, Texas from NextStage Clinical Research. The sites bring experienced research teams, established community provider relationships, and an active portfolio of cardiovascular trials to Iterative Health’s global site network. Financial terms were not disclosed.
The acquired sites join Iterative Health’s network of more than 100 sites across three continents. Iterative Health provides centralized operational support, proprietary AI tools for patient recruitment and trial efficiency and end-to-end services across clinical, regulatory and financial functions. The addition deepens the company’s capabilities in cardiovascular research, a high-need therapeutic area, complementing its existing focus in gastroenterology, hepatology and obesity.
The transaction builds on Iterative Health’s April 2026 strategic partnership with US Heart & Vascular and its $77 million Series C funding round to expand community-based cardiology research. The sites will continue serving local patients while gaining access to Iterative Health’s broader infrastructure and sponsor relationships.
According to data captured in the LevinPro HC database, this transaction represents the 38th Life Sciences R&D acquisition of the year, and the sixth in the clinical trial specialty. Other acquirers in the clinical trials space this year include Alcanza Clinical Research (acquired Tampa Bay Medical Research), Hippocratic AI (acquired Grove AI), PhaseWell Research (acquired Bio Behavioral Health and acquired Chase Medical Research) and Strados Labs (acquired NuvoAir Clinical Trials). There were 24 clinical trial deals announced in 2025, 27 deals in 2024 and 42 deals in 2023.
